The role of epigenetic modifications in drug resistance and treatment of breast cancer.

BACKGROUND: Breast cancer is defined as a biological and molecular heterogeneous disorder that originates from breast cells. Genetic predisposition is the most important factor giving rise to this malignancy. The most notable mutations in breast cancer occur in the BRCA1 and BRCA2 genes. Owing to disease heterogeneity, lack of therapeutic target, anti-cancer drug resistance, residual disease, and recurrence, researchers are faced with challenges in developing strategies to treat patients with breast cancer. RESULTS: It has recently been reported that epigenetic processes such as DNA methylation and histone modification, as well as microRNAs (miRNAs), have potently contributed to the pathophysiology, diagnosis, and treatment of breast cancer. These observations have persuaded researchers to move their therapeutic approaches beyond the genetic framework toward the epigenetic concept. CONCLUSION: Herein we discuss the molecular and epigenetic mechanisms underlying breast cancer progression and resistance as well as various aspects of epigenetic-based therapies as monotherapy and combined with immunotherapy.

Synthesis of two novel bio-based hydrogels using sodium alginate and chitosan and their proficiency in physical immobilization of enzymes.

Herein, four novel and bio-based hydrogel samples using sodium alginate (SA) and chitosan (CH) grafted with acrylamide (AAm) and glycidyl methacrylate (GMA) and their reinforced nanocomposites with graphene oxide (GO) were synthesized and coded as SA-g-(AAm-co-GMA), CH-g-(AAm-co-GMA), GO/SA-g-(AAm-co-GMA), and GO/CH-g-(AAm-co-GMA), respectively. The morphology, net charge, and water absorption capacity of samples were entirely changed by switching the biopolymer from SA to CH and adding a nano-filler. The proficiencies of hydrogels were compared in the immobilization of a model metagenomic-derived xylanase (PersiXyn9). The best performance was observed for GO/SA-g-poly(AAm-co-GMA) sample indicating better stabilizing electrostatic attractions between PersiXyn9 and reinforced SA-based hydrogel. Compared to the free enzyme, the immobilized PersiXyn9 on reinforced SA-based hydrogel showed a 110.1% increase in the released reducing sugar and almost double relative activity after 180 min storage. While immobilized enzyme on SA-based hydrogel displayed 58.7% activity after twelve reuse cycles, the enzyme on CH-based carrier just retained 8.5% activity after similar runs.